Evidence map›Paper›PMID 38339883›Full record

ArticlePharmacology research & perspectives2024

Inhibition of PDE-4 isoenzyme attenuates frequency and overall contractility of agonist-evoked ureteral phasic contractions.

Iris Lim, Taishi Masutani, Hikaru Hashitani, Russ Chess-Williams, Donna Sellers

Open access · goldAbstract read
In one paragraph

Article in Pharmacology research & perspectives, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Iris LimCentre for Urology, Faculty of Health Sciences & Medicine, Bond University, Gold Coast, Queensland, Australia.ORCID https://orcid.org/0000-0001-5866-8968
Taishi MasutaniDepartment of Cell Physiology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Hikaru HashitaniDepartment of Cell Physiology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Russ Chess-WilliamsCentre for Urology, Faculty of Health Sciences & Medicine, Bond University, Gold Coast, Queensland, Australia.
Donna SellersDepartment of Cell Physiology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Nagoya City University · JPBond University · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this study was to investigate the functional role of phosphodiesterase enzymes (PDE) in the isolated porcine ureter. Distal ureteral strips were mounted in organ baths and pre-contracted with 5-HT (100 μM). Upon generation of stable phasic contractions, PDE-4 and PDE-5 inhibitors were added cumulatively to separate tissues. PDE-4 inhibitors, such as rolipram (10 nM and greater) and roflumilast (100 nM and greater), resulted in significant attenuation of ureteral contractile responses, while a higher concentration of piclamilast (1 μM and greater) was required to induce a significant depressant effect. The attenuation effect by rolipram was abolished by SQ22536 (100 μM). PDE-5 inhibitors, such as sildenafil and tadalafil, were not nearly as effective and were only able to suppress the 5-HT-induced contractions at higher concentrations of 1 μM. Rolipram significantly enhanced the depressant effect of forskolin, while sodium nitroprusside-induced attenuation of contractile responses remained unchanged in the presence of tadalafil. In summary, our study demonstrates that PDE-4 inhibitors are effective in attenuating 5-HT-induced contractility in porcine distal ureteral tissues, while PDE-5 inhibitors are less effective. These findings suggest that PDE-4 inhibitors, such as rolipram, may hold promise as potential therapeutic agents for the treatment of ureteral disorders attributable to increased intra-ureteral pressure.

Indexed as

Phosphodiesterase 4 InhibitorsUreterAnimalsCyclic Nucleotide Phosphodiesterases, Type 4IsoenzymesPhosphodiesterase 5 InhibitorsRolipramSerotoninSwineTadalafilCyclic Nucleotide Phosphodiesterases, Type 4IsoenzymesPhosphodiesterase 4 InhibitorsPhosphodiesterase 5 InhibitorsRolipramSerotoninTadalafilphasic contractionsphosphodiesterasephosphodiesterase inhibitorsroflumilastrolipramsildenafiltadalafilureterurolithiasis

Identifiers

PMID38339883
PMCPMC10858371
OpenAlexW4391723144

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.